3
edits
Changes
m
no edit summary
Line 1:
Line 1:
'''
'''
'''O'Neal-Moffitt agenda: Dose response curve for pretreatment with anti-motion sickness ([http://en.wikipedia.org/wiki/Scopolamine Scopolamine] HBr) before magnet'''
'''O'Neal-Moffitt agenda: Dose response curve for pretreatment with anti-motion sickness ([http://en.wikipedia.org/wiki/Scopolamine Scopolamine] HBr) before magnet'''
+
'''Note:''' DRC followup from expt GA (Scopolamine HBr 5mg/ml/kg 30 minutes prior to magnet exposure)
'''Note:''' DRC followup from expt GA (Scopolamine HBr 5mg/ml/kg 30 minutes prior to magnet exposure)
'''Note:''' Scopolamine HBr acts both centrally and peripherally; Scopolamine Methyl Nitrate acts only peripherally.
'''Note:''' Scopolamine HBr acts both centrally and peripherally; Scopolamine Methyl Nitrate acts only peripherally.
+
Golding JF. Motion sickness susceptibility. Auton Neurosci. 2006 Oct 30;129(1-2):67-76. Epub 2006 Aug 23. Review. PMID 16931173
Golding JF. Motion sickness susceptibility. Auton Neurosci. 2006 Oct 30;129(1-2):67-76. Epub 2006 Aug 23. Review. PMID 16931173
+
Xu-Hong Yu. A novel animal model for motion sickness and its first application in rodents. Physiology & Behavior 2007; [http://dx.doi.org/10.1016/j.physbeh.2007.05.067 DOI]
Xu-Hong Yu. A novel animal model for motion sickness and its first application in rodents. Physiology & Behavior 2007; [http://dx.doi.org/10.1016/j.physbeh.2007.05.067 DOI]
+
-Subjects: 24 female Sprague-Dawley rats weighing 200-275g
-Subjects: 24 female Sprague-Dawley rats weighing 200-275g